Coverage of medical services and prescription medications for the treatment of dementia required, and step therapy requirements for medical assistance modified.
Summary
HF1269 would require Minnesota health plan companies to cover all FDA-approved medical services and prescription medications used to treat or slow the progression of dementia, along with diagnostic testing needed to determine whether a treatment is appropriate or effective. The bill also bars health plans from using step therapy for the dementia-related coverage required by the bill. These new coverage requirements would apply to health plans offered, issued, or renewed on or after January 1, 2026.
The bill also amends Minnesota’s Medical Assistance prior authorization rules. It adds dementia-related step therapy requirements to the existing statute governing prior authorization and directs that any step therapy protocols used by the commissioner must comply with the new dementia coverage law. The amendment also clarifies that these step therapy requirements apply to fee-for-service delivery under Medical Assistance, while leaving the broader prior authorization framework in place for other drugs and conditions.
Impact
The bill would create a new insurance coverage mandate in Minnesota Statutes chapter 62Q for dementia treatment and diagnostics, expanding required benefits for private health plans. It would also modify Minnesota Statutes section 256B.0625, subdivision 13f, by tying Medical Assistance step therapy rules to the new dementia coverage standards and requiring compliance in fee-for-service delivery. In practical terms, insurers and the Medicaid program would need to cover a broader set of dementia therapies without forcing patients through step therapy barriers for those services.
Sentiment
The available record suggests the bill is being advanced as a patient-access measure, with no recorded committee transcript or vote history showing opposition or support. Based on the bill’s structure and caption, the overall tone appears favorable toward expanding access to dementia care and reducing utilization-management barriers. Because no hearings or votes are provided, there is no documented public sentiment beyond the bill’s pro-coverage design.
Contention
The main policy issue raised by the bill is the restriction on step therapy, which limits insurers’ ability to require patients to try less expensive treatments before covering dementia therapies. That could be a point of concern for health plans and cost-containment advocates, who may view the mandate as reducing flexibility and increasing expenditures. On the other hand, supporters would likely emphasize timely access to treatment, diagnostic testing, and continuity of care for people living with dementia. No specific objections or amendments are included in the provided record.
Similar To
Dementia treatment medical services and prescription medications coverage requirement provision and step therapy requirements for medical assistance provision